United States
A physician scientist trained in Cardiovascular Medicine, Metabolism, Kidney and Orphan Disease, in both pre-clinical and clinical pharmaceutical research, seeking a role of medical lead in innovative therapeutic advances. Education: 1. MD 2. PhD, Biochemstry 3. Internal Medicine/Cardiology Research in Pharmaceutical Industry • 2026-present. Wave Life Sciences. Global Clinical Head to lead the early- and late-stage development of RNA-based therapies in cardiometabolic diseases (obesity, MASH, dyslipidemia). • 2023-2026. Novartis. Senior Global Program Clinical Head to lead the late-stage development (Ph3 pivotal) of innovative therapies for glomerular kidney diseases. • 2021-2022. AstraZeneca. Executive Medical Director and Global Clinical Lead to lead the early-stage development (portfolio entry to seamless Ph2/3) of novel mechanisms of anti-inflammatory therapies for heart failure (HFrEF and HFpEF), kidney and metabolic diseases • 2018-2020. Eli Lilly. Medical Director to lead the global early-stage development (Ph2 and seamless 2/3) of inflammatory complications of type-2 diabetes: heart failure (HFrEF and HFpEF), vasculopathy, NASH, obesity and chronic kidney disease • 2014-2018. Amgen. Medical Director to lead the early-stage (Ph1 and 2) and late-stage (Ph 3 and 4) development of new therapies for cardiovascular (HFrEF and HFpEF), metabolic and neurological diseases. • 2010-2013. Merck. Medical Director to lead the late-stage development (Ph3 pivotal) of lipid-modifying therapies Pre-clinical and Translational Research in Academia 2000-2010. University of Medicine and Dentistry of New Jersey. Laboratory Head and Associate Professor (tenure) of Cell Biology to study the functional genomics of cancer-related genes. Funding from National Institutes of Health (NIH) and American Heart Association (AHA), ≥100 peer-reviewed publications, presentations at scientific meetings, AHA scientific awards, OL networking. Responsibilities in Drug Development: Global team lead in a matrix environment Design and medical monitoring of clinical trials NDA and BLA filings, regulatory approval and launch IND applications and pre-IND meetings Global strategy of clinical development plans from portfolio entry to pivotal studies Life cycle management and evidence generation planning Creation and review of clinical, regulatory, biostatistics, safety and label documents External interactions and networking with KOLs, CROs, clinical sites and scientific organizations
Glomerular and Kidney Disease
Heart failure with preserved and reduced ejection fraction
Diabetes complications and Obesity
Novel Therapies for Heart Failure